Selected article for: "early onset and treatment early onset"
Author: Gentile, Giorgio; Davies, Rebecca; Manfreda, Valeria Maria; Ul Abideen, Zain
Title: Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
  • Cord-id: e0k8gqgq
  • Document date: 2021_1_8
    • ID: e0k8gqgq
    Snippet: As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizu
    Document: As of 28 October 2020, there are over 44 000 000 confirmed COVID-19 infections and over 1 000 000 deaths worldwide, including 945 367 infections and 45 765 deaths in the UK. Acute respiratory distress syndrome occurs in 50% of patients with secondary haemophagocytic lymphohistiocytosis, a hyperinflammatory syndrome characterised by a surge of cytokines, including interleukin 6 (IL-6). Here we describe the case of the first patient with severe COVID-19 pneumonia successfully treated with tocilizumab, a humanised monoclonal antibody against the IL-6 receptor, in the UK. Early treatment (after 7–10 days from the onset of symptoms) with tocilizumab could (1) reduce the risk of requiring non-invasive or invasive ventilation; (2) offer a chance of survival to people who are not fit for escalation or have refused to be ventilated; and (3) potentially increase the chance of survival in some patients who are already ventilated but fail to improve with supportive treatment.

    Search related documents:
    Co phrase search for related documents
    • absolute contraindication and acute ards respiratory distress syndrome: 1
    • absolute contraindication and acute respiratory distress: 1
    • accurate classification and acute respiratory distress: 1
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and acute deterioration: 1, 2
    • active infection and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • active infection and lung damage: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and admission ray: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome develop and lung damage: 1, 2, 3, 4, 5, 6, 7, 8
    • acute deterioration and admission ray: 1
    • acute deterioration and lung damage: 1
    • acute respiratory distress and additional complication: 1, 2
    • acute respiratory distress and admission ray: 1, 2, 3, 4
    • acute respiratory distress and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25